6 Dimensions Capital is set to exit immuno-oncology drug developer TCR² Therapeutics in an offering likely to raise between $70m and $80m.

TCR² Therapeutics, a US-based cancer immunotherapy developer backed by pharmaceutical firm WuXi AppTec, has set the terms for an initial public offering that would raise $80m at its upper end. The company intends to issue 5 million shares on the Nasdaq Global Market priced between $14 and $16 per share, which would put the size…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.